Anna Kalff

Commercial Road
Prahran, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Journal: Internal medicine journal

Published: August 27, 2025

Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma.

Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma.

Journal: Leukemia & lymphoma

Published: October 15, 2024

Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma.

Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma.

Journal: Blood cancer journal

Published: September 10, 2024

A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16).

A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16).

Journal: British journal of haematology

Published: March 16, 2023

Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial.

Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial.

Journal: British journal of haematology

Published: January 25, 2023

Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma.

Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma.

Journal: Blood cancer journal

Published: December 06, 2022

The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia.

The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia.

Journal: Internal medicine journal

Published: April 14, 2022

The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice.

The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice.

Journal: Frontiers in oncology

Published: November 23, 2021

Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD).

Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD).

Journal: Leukemia & lymphoma

Published: July 15, 2021

Upfront tandem autologous non-myeloablative allogeneic stem cell transplant in high-risk multiple myeloma: a long-term single-centre experience.

Upfront tandem autologous non-myeloablative allogeneic stem cell transplant in high-risk multiple myeloma: a long-term single-centre experience.

Journal: Internal medicine journal

Published: July 12, 2021

Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia.

Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia.

Journal: Internal medicine journal

Published: April 29, 2021

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14).

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14).

Journal: Haematologica

Published: February 24, 2021

Showing 1-12 of 35

Last Updated: 09/26/2026